Med-IQ
Influenza Treatment and Prophylaxis in the 2021-2022 Flu Season: Educating Providers and Empowering Patients

Influenza Treatment and Prophylaxis in the 2021-2022 Flu Season: Educating Providers and Empowering Patients

Webcast
Continue to Course
Online Course | Specialties: Emergency Medicine, Family Medicine, Internal Medicine
Released: 12/14/2021
|
Expires: 12/13/2022
|
Max Credits: 0.5
Continue to Course Read Abstract

Faculty
Brittani James, MD
Medical Director, IMAN Community Health Center
Cofounder, The Institute for Antiracism in Medicine
Assistant Clinical Professor, Department of Family and Community Medicine
University of Illinois College of Medicine
Chicago, IL
 
Rishi Desai, MD, MPH
Chief Medical Officer
Pediatric Infectious Diseases
Osmosis
Oakland, CA

Activity Planners
Genevieve Olucha, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD 

Samantha Gordon, MS
Accreditation Manager 
Med-IQ
Baltimore, MD
 
Amy Sison
Director of CME
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM, CHCP
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:
  • Describe strategies to enable the prompt and accurate diagnosis of influenza in adult patients
  • Differentiate among available and emerging antivirals in terms of safety, efficacy, mechanism of action, indications, and utility within the influenza treatment/prevention paradigm
  • Integrate patient engagement and education strategies into personalized influenza treatment/prevention plans

Target Audience
This activity is intended for clinicians in primary care, emergency medicine, and urgent care.

Statement of Need
Influenza is a disease that leads to significant public health burden, causing substantial morbidity and mortality through seasonal spread and pandemics. Diagnostic delays limit the opportunity to administer critical antiviral treatments and prevention strategies, thereby putting patients at risk of potentially life-threatening complications. Moreover, certain individuals are at high risk of severe disease or complications, such as older persons, immunocompromised individuals, or those with chronic health conditions. The continuous evolution of the influenza virus and the emergence of resistance to traditional antiviral therapies underscore the need for additional antiviral therapies. The approval of novel antivirals, evolving data on current and emerging treatments, and limited guidance present challenges on how to optimally incorporate the latest advances into personalized influenza treatment and prevention plans. Additionally, many patients harbor concerns or misconceptions or are misinformed regarding influenza and its treatment, creating a barrier to optimal care. Therefore, clinicians can benefit from guidance on available antiviral treatments and chemoprophylaxis to make informed, evidenced-based decisions regarding patient management and transmission prevention.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC from the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique, six-digit ABIM ID Number. Please note, your name, ABIM ID number, birthdate and completion status will be shared with ABIM through the ACCME PARS system. Your points will be automatically submitted to the ABIM on your behalf; please allow 4 weeks for your points to display on the ABIM website.

Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
 
This nursing activity has been approved for up to 0.5 contact hour.

Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: December 14, 2021
Expiration Date: December 13, 2022
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Rishi Desai, MD, MPH, has indicated no real or apparent conflicts.
 
Brittani James, MD, has indicated no real or apparent conflicts.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.


Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Copyrighted

Abstract
Here are some key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available by clicking the "Continue" button below.
  • Influenza is a disease that leads to significant public health burden, causing substantial morbidity and mortality
  • Diagnostic delays limit the opportunity to administer critical antiviral treatments and prevention strategies, thereby putting patients at risk of potentially life-threatening complications
  • Certain individuals have a high risk of severe disease or complications, such as older persons, immunocompromised individuals, or those with chronic health conditions
  • Many patients harbor concerns or misconceptions or are misinformed regarding influenza and its treatment, creating a barrier to optimal care
  • The approval of novel antivirals, evolving data on current and emerging treatments, and limited guidance present challenges on how to optimally incorporate the latest advances into personalized influenza treatment and prevention plans
  • Four FDA-approved antiviral medications are available in the US: oseltamivir, zanamivir, peramivir, and baloxavir marboxil, each with its own safety and efficacy profile, resistance issues, dosing, indications, and adherence guidelines
  • Antiviral treatment should be initiated immediately, ideally no later than 48 hours after the start of symptoms
  • Chemoprophylaxis with antiviral medications can be used to help prevent the spread of influenza

View reference list.

Click "Continue" to proceed through this activity and/or receive credit.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.